HB9 Regulators for Pancreatic Endocrine Cell Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge in differentiating human embryonic stem cells into functional pancreatic endocrine cells, particularly β cells, is complex and inefficient, with existing protocols struggling to effectively regulate HB9 expression and produce mature β cells in vitro.
Innovation Solution
The use of thyroid hormones, such as T3 and T4, or their analogues, in combination with ALK5 inhibitors in a specific culturing sequence to induce HB9 protein expression and differentiate stem cells into pancreatic endoderm cells positive for NKX6.1, PDX1, and HB9, facilitating the generation of β cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing differentiation protocols are used, then stem cells can be differentiated into pancreatic endoderm cells, but the efficiency is low and HB9 expression is not effectively regulated
Solution Approach 1:
The patent applies parameter changes by systematically optimizing the concentration, timing, and sequence of differentiation factors (such as retinoic acid, FGF10, and other signaling molecules) to control HB9 expression levels. By adjusting these parameters, the protocol achieves both high differentiation efficiency and reliable HB9 regulation, resolving the contradiction between productivity and reliability.
Solution Approach 2:
The patent employs preliminary action by pre-establishing specific culture conditions and factor addition sequences before the differentiation process begins. The protocol includes pre-differentiation steps that prepare stem cells for efficient HB9 expression, ensuring that when differentiation is initiated, the cells are primed to respond optimally, thereby achieving both high efficiency and reliable gene expression control.
2Quantity of substance
If complex differentiation protocols are applied, then more pancreatic endocrine cells can be produced, but the process becomes less efficient and more difficult to control
Solution Approach 1:
The patent applies segmentation by dividing the differentiation process into distinct, manageable stages with specific objectives for each phase. The protocol separates the complex process into sequential steps (e.g., endoderm formation, pancreatic progenitor specification, endocrine differentiation), allowing each stage to be optimized independently while maintaining overall efficiency and control.
Solution Approach 2:
The patent uses partial action by applying differentiation factors at specific concentrations and time windows rather than continuous maximum dosing. This approach achieves sufficient HB9 expression and pancreatic endocrine cell production without the need for overly complex protocols, maintaining simplicity while ensuring adequate cell yield.
Data Source
AI summary
The present invention provides methods to promote differentiation of pluripotent stem cells to pancreatic endoderm cells expressing PDX1, NKX6.1, and HB9. In particular, the methods encompass culturing Stage 4 to Stage 6 cells with a thyroid hormone (e.g. T3), an ALK5 inhibitor, or both.